Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity

Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and antagonists, which display promising therapeutic activities in cancer and autoimmunity, respectively. We previously showed that epitope and isotype interact to deliver optimal agonistic anti-CD40 mAbs. The impact of Fc engineering on antag...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Cell
Prif Awduron: Yu, Xiaojie, Chan, H.T. Claude, Fisher, Hayden, Penfold, Christine A., Kim, Jinny, Inzhelevskaya, Tatyana, Mockridge, C. Ian, French, Ruth R., Duriez, Patrick J., Douglas, Leon R., English, Vikki, Verbeek, J. Sjef, White, Ann L., Tews, Ivo, Glennie, Martin J., Cragg, Mark S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Cell Press 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280789/
https://ncbi.nlm.nih.gov/pubmed/32442402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2020.04.013
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg